Platelet alpha 2-adrenergic receptor function in psychiatric disorders.
The inhibitory effects of norepinephrine (NE) on the cyclic adenosine-3',5'-monophosphate (cAMP) response to prostaglandin E1 (PGE1), a measure of alpha 2-adrenergic receptor function, have been compared in platelets from drug-free schizophrenic patients, depressive patients, and normal controls. The absolute value of the inhibition by NE of the cAMP response to PGE1 was smaller in platelets from schizophrenic and depressive patients than in controls. However, this result was secondary to the smaller baseline platelet cAMP response to PGE1 in patients with these disorders. Effects of NE on cAMP production did not discriminate between actively ill and remitted patients with either schizophrenia or depression. Platelet alpha 2-receptor sensitivity, as measured by the effects of NE on cAMP production, does not appear to be altered in these psychiatric disorders.
Kanof
P D
PD
Psychiatry Service, Bronx VA Medical Center, NY 10468.
Johns
C A
CA
Davidson
M
M
Siever
L J
LJ
Coccaro
E F
EF
Davis
K L
KL
D000328:Adult; D001792:Blood Platelets / Q000378:metabolism*; D000242:Cyclic AMP / Q000097:blood; D003866:Depressive Disorder / Q000097:blood* / Q000523:psychology; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000097:blood; D011569:Psychiatric Status Rating Scales; D011941:Receptors, Adrenergic / Q000378:metabolism*; D012559:Schizophrenia / Q000097:blood*; D012565:Schizophrenic Psychology
D011941:Receptors, Adrenergic; D000242:Cyclic AMP; D009638:Norepinephrine